160 related articles for article (PubMed ID: 30198022)
1. The Benefits of Genetic Addiction Risk Score (GARS
Blum K; Modestino EJ; Gondre-Lewis M; Chapman EJ; Neary J; Siwicki D; Baron D; Hauser M; Smith DE; Roy AK; Thanos PK; Steinberg B; McLaughlin T; Fried L; Barh D; Dunston GA; Badgaiyan RD
Int J Genom Data Min; 2018; 2018(1):. PubMed ID: 30198022
[TBL] [Abstract][Full Text] [Related]
2. Genetic Addiction Risk Severity Assessment Identifies Polymorphic Reward Genes as Antecedents to Reward Deficiency Syndrome (RDS) Hypodopaminergia's Effect on Addictive and Non-Addictive Behaviors in a Nuclear Family.
Dennen CA; Blum K; Bowirrat A; Thanos PK; Elman I; Ceccanti M; Badgaiyan RD; McLaughlin T; Gupta A; Bajaj A; Baron D; Downs BW; Bagchi D; Gold MS
J Pers Med; 2022 Nov; 12(11):. PubMed ID: 36579592
[TBL] [Abstract][Full Text] [Related]
3. Exploration of Epigenetic State Hyperdopaminergia (Surfeit) and Genetic Trait Hypodopaminergia (Deficit) During Adolescent Brain Development.
Blum K; Bowirrat A; Gondre Lewis MC; Simpatico TA; Ceccanti M; Steinberg B; Modestino EJ; Thanos PK; Baron D; McLaughlin T; Brewer R; Badgaiyan RD; Ponce JV; Lott L; Gold MS
Curr Psychopharmacol; 2021 Feb; 10():. PubMed ID: 34707969
[TBL] [Abstract][Full Text] [Related]
4. Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms.
Blum K; Simpatico T; Badgaiyan RD; Demetrovics Z; Fratantonio J; Agan G; Febo M; Gold MS
J Reward Defic Syndr; 2015; 1(2):75-80. PubMed ID: 27617300
[TBL] [Abstract][Full Text] [Related]
5. Dopamine Genetics and Function in Food and Substance Abuse.
Blum K; Oscar-Berman M; Barh D; Giordano J; Gold M
J Genet Syndr Gene Ther; 2013 Feb; 4(121):. PubMed ID: 23543775
[TBL] [Abstract][Full Text] [Related]
6. Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation.
Blum K; Oscar-Berman M; Giordano J; Downs B; Simpatico T; Han D; Femino J
J Genet Syndr Gene Ther; 2012 Oct; 3(4):. PubMed ID: 23264886
[TBL] [Abstract][Full Text] [Related]
7. Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?
Blum K; Dennen CA; Elman I; Bowirrat A; Thanos PK; Badgaiyan RD; Downs BW; Bagchi D; Baron D; Braverman ER; Gupta A; Green R; McLaughlin T; Barh D; Gold MS
J Pers Med; 2022 Oct; 12(10):. PubMed ID: 36294858
[TBL] [Abstract][Full Text] [Related]
8. Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case-Control Subjects.
Blum K; Han D; Gupta A; Baron D; Braverman ER; Dennen CA; Kazmi S; Llanos-Gomez L; Badgaiyan RD; Elman I; Thanos PK; Downs BW; Bagchi D; Gondre-Lewis MC; Gold MS; Bowirrat A
J Pers Med; 2022 Aug; 12(9):. PubMed ID: 36143170
[TBL] [Abstract][Full Text] [Related]
9. "TO BE OR NOT TO BE" GWAS Ends the Controversy about the DRD2 Gene as a Determinant of Reward Deficiency Syndrome (RDS).
Blum K; Thanos PK; Hanna C; Gold MS; Baron D; Elman I
Psychol Res Behav Manag; 2023; 16():4287-4291. PubMed ID: 37885829
[TBL] [Abstract][Full Text] [Related]
10. Theorizing the Role of Dopaminergic Polymorphic Risk Alleles with Intermittent Explosive Disorder (IED), Violent/Aggressive Behavior and Addiction: Justification of Genetic Addiction Risk Severity (GARS) Testing.
Modestino EJ; Blum K; Dennen CA; Downs BW; Bagchi D; Llanos-Gomez L; Elman I; Baron D; Thanos PK; Badgaiyan RD; Braverman ER; Gupta A; Gold MS; Bowirrat A
J Pers Med; 2022 Nov; 12(12):. PubMed ID: 36556167
[TBL] [Abstract][Full Text] [Related]
11. The Future is Now for Precision Genomic Addiction Medicine as a Frontline Modality for Inducing "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).
Gilley ED; Bowirrat A; Gupta A; Giordano J; A Dennen C; R Braverman E; D Badgaiyan R; McLaughlin T; Baron D; Blum K
Curr Pharm Biotechnol; 2023 Apr; ():. PubMed ID: 37102488
[TBL] [Abstract][Full Text] [Related]
12. Evidence for the
Blum K; Bowirrat A; Elman I; Baron D; Thanos PK; Gold MS; Hanna C; Makale MT; Sunder K; Jafari N; Zeine F; Murphy KT; Makale M; Badgaiyan RD
Clin Exp Psychol; 2023 Jun; 9(4):8-11. PubMed ID: 37560184
[TBL] [Abstract][Full Text] [Related]
13. Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids.
Ceccanti M; Blum K; Bowirrat A; Dennen CA; Braverman ER; Baron D; Mclaughlin T; Giordano J; Gupta A; Downs BW; Bagchi D; Barh D; Elman I; Thanos PK; Badgaiyan RD; Edwards D; Gold MS
J Pers Med; 2022 Dec; 12(12):. PubMed ID: 36556236
[TBL] [Abstract][Full Text] [Related]
14. Genetic Addiction Risk and Psychological Profiling Analyses for "Preaddiction" Severity Index.
Blum K; Han D; Bowirrat A; Downs BW; Bagchi D; Thanos PK; Baron D; Braverman ER; Dennen CA; Gupta A; Elman I; Badgaiyan RD; Llanos-Gomez L; Khalsa J; Barh D; McLaughlin T; Gold MS
J Pers Med; 2022 Oct; 12(11):. PubMed ID: 36579510
[TBL] [Abstract][Full Text] [Related]
15. The benefits of genetic addiction risk score (GARS™) and pro-dopamine regulation in combating suicide in the American Indian population.
Blum K; Siwicki D; Baron D; Modestino EJ; Badgaiyan RD
J Syst Integr Neurosci; 2018 Sep; 4():. PubMed ID: 31660252
[TBL] [Abstract][Full Text] [Related]
16. GLOBAL OPIOID EPIDEMIC: DOOMED TO FAIL WITHOUT GENETICALLY BASED PRECISION ADDICTION MEDICINE (PAM
Blum K; Modestino EJ; Gondré-Lewis MC; Neary J; Siwicki D; Hauser M; Barh D; Steinberg B; Badgaiyan RD
Precis Med (Bangalore); 2017; 2(1):17-22. PubMed ID: 29372187
[TBL] [Abstract][Full Text] [Related]
17. Summary Document Research on RDS Anti-addiction Modeling: Annotated Bibliography.
Blum K; Baron D; McLaughlin T; Thanos PK; Dennen C; Ceccanti M; Braverman ER; Sharafshah A; Lewandrowski KU; Giordano J; Badgaiyan RD
J Addict Psychiatry; 2024 Apr; 8(1):1-33. PubMed ID: 38765881
[TBL] [Abstract][Full Text] [Related]
18. Endorphinergic Enhancement Attenuation of Post-traumatic Stress Disorder (PTSD)
Blum K; Modestino EJ; Baron D; Brewer R; Thanos P; Elman I; Badgaiyan RD; Downs BW; Bagchi D; McLaughlin T; Bowirrat A; Roy AK; Gold MS
Curr Psychopharmacol; 2021 Aug; 10(2):86-97. PubMed ID: 34466374
[TBL] [Abstract][Full Text] [Related]
19. Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy: Fighting Iatrogenic Opioid Dependence.
Blum K; Oscar-Berman M; Dinubile N; Giordano J; Braverman ER; Truesdell CE; Barh D; Badgaiyan R
J Addict Res Ther; 2013 Oct; 4(163):1000163. PubMed ID: 24616834
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic dysfunction: Role for genetic & epigenetic testing in the new psychiatry.
Blum K; Ashford JW; Kateb B; Sipple D; Braverman E; Dennen CA; Baron D; Badgaiyan R; Elman I; Cadet JL; Thanos PK; Hanna C; Bowirrat A; Modestino EJ; Yamamoto V; Gupta A; McLaughlin T; Makale M; Gold MS
J Neurol Sci; 2023 Oct; 453():120809. PubMed ID: 37774561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
